Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

European Journal of Cancer

Volumn 42, Issue 14, 2006, Pages 2335-2342

  Baruchel, S ^a   Diezi, M ^a   Hargrave, D ^a   Stempak, D ^a   Gammon, J ^a   Moghrabi, A ^b   Coppes, M J ^c   Fernandez, C V ^d   Bouffet, E ^e  

^a Division of Haematology/Oncology   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Brain tumour; Child; Dose escalation; Metronomic; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; EVALUATION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HUMAN; LETHARGY; LYMPHOCYTOPENIA; MALE; MEDULLOBLASTOMA; MOTOR PERFORMANCE; NEUTROPENIA; PRIORITY JOURNAL; RESTLESSNESS; THROMBOCYTOPENIA; TUMOR RECURRENCE; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHILD; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL;

EID: 33745764554     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.03.023     Document Type: Article

References (51)

1. Stevens M.F.G., Hickman J.A., Langdon S.P., et al. Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel drug with potential as an alternative dacarbazine. Cancer Res 47 (1987) 5846-5852
2. Newlands E.S., Blackledge G.R., Slack J.A., et al. Phase I trial of Temozolomide. Br J Cancer 65 (1992) 287-291
3. Ostermann S., Csajka C., Buclin T., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10 (2004) 3728-3736
4. Patel M., McCully C., Godwin K., et al. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neuro-oncol 61 (2003) 203-207
5. Abrey L.E., and Christodoulou C. Temozolomide for treating brain metastases. Semin Oncol 28 (2001) S34-S42
6. Chinot O. Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 28 (2001) S13-S18
7. Macdonald D.R. Temozolomide for recurrent high-grade glioma. Semin Oncol 28 (2001) S3-S12
8. Prados M.D. Temozolomide in combination with other cytotoxic agents. Semin Oncol 28 (2001) S24-S33
9. Stupp R., Gander M., and Leyvraz S. Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncol 2 (2001) 552-560
10. Newlands E.S., Stevens M.F.G., Wedge S.R., et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23 (1997) 35-61
11. Friedman H.S., Kerby T., and Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 6 (2000) 2585-2597
12. Yung W.K., Prados M.D., and Yaya-Tur R. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17 (1999) 2762-2771
13. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastomas multiforme at first relapse. Br J Cancer 83 (2000) 588-593
14. Quinn J.A., Reardon D.A., Friedman A.H., et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21 (2003) 646-651
15. Stupp R., and Newlands E.S. New approaches for temozolomide therapy: use in newly diagnosed glioma. Semin Oncol 28 (2001) S19-S23
16. Stupp R., Dietrich P.Y., Ostermann S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 (2002) 1375-1382
17. Middlemas D.S., Stewart C.F., Kirstein M.N., et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6 (2000) 998-1007
18. Gerson S.L. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 20 (2002) 2388-2399
19. Hegi M.E., Diserens A.C., Godard S., et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10 (2004) 1871-1874
20. Tolcher A.W., Gerson S.L., Denis L., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
21. Estlin E.J., Lashford L.S., Ablett S., et al. Phase I study of temozolomide in paediatric patients with advanced cancer. Br J Cancer 78 (1998) 652-661
22. Lashford L.S., Thiesse P., Jouvet A., et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study. J Clin Oncol 20 (2003) 4684-4691
23. Kerbel R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13 (1991) 31-36
24. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105 (2000) R15-R24
25. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
26. Hanahan D., Bergers G., and Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105 (2000) 1045-1047
27. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
28. Brock C.S., Newlands E.S., Wedge S.R., et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58 (1998) 4363-4367
29. Khan R.B., Raizer J.J., Malkin M.G., et al. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol 4 (2002) 39-43
30. Sterba J., Pavleka Z., and Slampa P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 49 (2002) 117-120
31. Kuo D.J., Weiner H.L., Wisoff J., et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25 (2003) 372-378
32. Available from: http://ctep.cancer.gov/reporting/CTC-3test.html.
33. Gajewski T.F. Temozolomide for melanoma: new toxicities and new opportunities. J Clin Oncol 22 (2004) 580-581
34. Gilbert M.R., Friedman H.S., Kuttesch J.F., et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol 4 (2002) 261-267
35. Jaeckle K.A., Hess K.R., Yung W.K., et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment or recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21 (2003) 2305-2311
36. Hargrave D., Bouffet E., Gammon J., Becker L., Rutka J., and Baruchel S. Response to low dose temozolomide in radiation induced gliomatosis cerebri. Med Pediatr Oncol 41 (2003) 562-564
37. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352 (2005) 987-996
38. Emmenegger U., Man S., Shaked Y., et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 64 (2004) 3994-4000
39. Kurzen H., Schmitt S., Näher H., et al. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14 (2003) 515-522
40. Spieth K., Kaufmann R., and Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 52 (2003) 377-382
41. Vogt T., Hafner C., Bross K., et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 98 (2003) 2251-2256
42. Glode L.M., Barqawi A., Crighton F., et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. [See comment]. Cancer 98 (2003) 1643-1648
43. Hahnfeldt P., Folkman J., and Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 220 (2003) 545-554
44. Gately S., and Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 7 (2001) 427-436
45. Franceschi E., Omuro A.M., Lassman A.B., Demopoulos A., Nolan C., and Abrey L.E. Salvage temozolomide for prior temozolomide responders. Cancer 104 (2005) 2473-2476
46. Riccardi A., Mazzarella G., Cefalo G., et al. Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients. Cancer Chemother Pharmacol 52 (2003) 459-464
47. Panetta J.C., Kirstein M.N., Gaiiar A., et al. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52 (2003) 435-441
48. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22 (2004) 610-616
49. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 (2003) 4342-4346
50. Shaked Y., Bertolini F., Man S., et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7 (2005) 101-111
51. Maraveyas A., Lam T., Hetherington J.W., et al. Can a rational design for metronomic chemotherapy dosing be devised?. Br J Cancer 92 (2005) 1588-1590